- Home
- LNG vs TAK Comparison
LNG vs TAK Comparison
Compare LNG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNG
- TAK
- Stock Information
- Founded
- LNG 1983
- TAK 1781
- Country
- LNG United States
- TAK Japan
- Employees
- LNG N/A
- TAK N/A
- Industry
- LNG Oil/Gas Transmission
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- LNG Utilities
- TAK Health Care
- Exchange
- LNG Nasdaq
- TAK Nasdaq
- Market Cap
- LNG 40.7B
- TAK 43.9B
- IPO Year
- LNG 1997
- TAK N/A
- Fundamental
- Price
- LNG $222.66
- TAK $13.37
- Analyst Decision
- LNG Strong Buy
- TAK
- Analyst Count
- LNG 9
- TAK 0
- Target Price
- LNG $206.44
- TAK N/A
- AVG Volume (30 Days)
- LNG 2.0M
- TAK 1.8M
- Earning Date
- LNG 10-31-2024
- TAK 10-31-2024
- Dividend Yield
- LNG 0.90%
- TAK 4.73%
- EPS Growth
- LNG N/A
- TAK 49.73
- EPS
- LNG 15.70
- TAK 1.27
- Revenue
- LNG $15,579,000,000.00
- TAK $31,732,209,416.00
- Revenue This Year
- LNG N/A
- TAK $4.41
- Revenue Next Year
- LNG $15.18
- TAK $1.09
- P/E Ratio
- LNG $14.18
- TAK $20.80
- Revenue Growth
- LNG N/A
- TAK 9.43
- 52 Week Low
- LNG $152.31
- TAK $12.58
- 52 Week High
- LNG $225.27
- TAK $15.08
- Technical
- Relative Strength Index (RSI)
- LNG 75.64
- TAK 35.93
- Support Level
- LNG $207.42
- TAK $13.21
- Resistance Level
- LNG $225.27
- TAK $13.75
- Average True Range (ATR)
- LNG 4.81
- TAK 0.15
- MACD
- LNG 1.75
- TAK -0.02
- Stochastic Oscillator
- LNG 92.83
- TAK 15.53
About LNG Cheniere Energy Inc.
Cheniere Energy owns and operates the Sabine Pass liquefied natural gas terminal via its stake in Cheniere Partners. It also owns the Corpus Christi LNG terminals as well as Cheniere Marketing, which markets LNG using Cheniere's gas volumes.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.